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Abstract
Background: Disparities in cancer survival by socioeconomic status have been reported previously in Australia. We
investigated whether those disparities have changed over time.
Methods: We used population-based cancer registry data for 377,493 patients diagnosed with one of 10 major
cancers in New South Wales (NSW), Australia. Patients were assigned to an area-based measure of socioeconomic
status. Five-year relative survival was estimated for each socioeconomic quintile in each ‘at risk’ period (1996–2000
and 2004–2008) for the 10 individual cancers. Poisson-regression modelling was used to adjust for several prognostic
factors. The relative excess risk of death by socioeconomic quintile derived from this modelling was compared over time.
Results: Although survival increased over time for most individual cancers, Poisson-regression models indicated
that socioeconomic disparities continued to exist in the recent period. Significant socioeconomic disparities were
observed for stomach, colorectal, liver, lung, breast and prostate cancer in 1996–2000 and remained so for 2004–2008,
while significant disparities emerged for cervical and uterus cancer in 2004–2008 (although the interaction between
period and socioeconomic status was not significant). About 13.4 % of deaths attributable to a diagnosis of cancer
could have been postponed if this socioeconomic disparity was eliminated.
Conclusion: While recent health and social policies in NSW have accompanied an increase in cancer survival overall,
they have not been associated with a reduction in socioeconomic inequalities.
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Background
Internationally, cancer patients from more socioeconomi-
cally disadvantaged backgrounds have been shown to have
poorer outcomes for many major cancers [1–4]. Similar
socioeconomic disparities in survival have also been
reported in Australia [5, 6]. In the few studies that have
monitored such disparities over time in a population, most
report either no change in the extent of disparities
detected or widening disparities, for several major cancers
[7–9]. Generally these studies report on only one or few
cancer types and involve limited adjustment for potential
prognostic factors.
In 2008, Yu et al reported that persons from more
socioeconomically disadvantaged areas of New South
Wales (NSW), Australia experienced poorer survival for
many types of cancer than those from the least disad-
vantaged areas [6]. These disparities are well recognised
by health professionals and providers; however there is
little knowledge about whether these socioeconomic
disparities in cancer survival have reduced over time.
The purpose of this study is to determine whether the
socioeconomic variations in cancer survival for 10 major
cancers in NSW, Australia have changed over time, after
account for the impact of demographics and tumour
characteristics.
Methods
Data were obtained from the population-based NSW
Central Cancer Registry for all patients aged 15–89 years
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at the time of their diagnosis of a primary cancer
between January 1991 and December 2008. Notification
of cancer diagnosis to the registry is a statutory require-
ment in NSW. We included ten cancers with high inci-
dence and large contribution to mortality (see Table 1),
defined by International Classification of Diseases for
Oncology 3rd Edition codes [10].
Cases were followed up for survival status up to the 31
December 2008 through record linkage of the cancer
cases in the Cancer Registry with death records from the
NSW Register of Births, Deaths and Marriages and the
National Death Index. Cases notified to the registry by
death certificate only or first identified at post-mortem
were excluded.
To maintain comparability with the previously men-
tioned study by Yu and colleagues [6], we used an
area-based socioeconomic measure, the “Index of
Education and Occupation” score. This is a composite
index of relative advantage, based on data from the
national Australian census [11]. Index scores derived
from the 2001 census were used to classify the in-
cluded cases by socioeconomic status (SES) in both
analysis periods. An area with a high index score indicates
a relatively high level of educational attainment and skilled
employment of the resident population. Socioeconomic
quintiles were created by ranking the index score of all the
Local Government Areas (LGA) in NSW. In 2001 there
were 175 LGAs in NSW, ranging from small urban areas
with large populations to extremely large rural areas with
small populations, each with an average population of
35,954 residents (IQR: 4713–43,809) [ABS Online data
2001]. Cases were excluded from analysis if they had in-
sufficient information to assign an LGA or if index scores
were not available.
Disease stage at diagnosis was based on pathology
reports and statutory notifications by hospitals, then
coded using a modified summary classification: localised
(stage I), regional (a combination of stages II and III),
distant (stage IV) and unknown (including missing) stage.
Statistical Analysis
Relative survival, the ratio of the observed proportion
surviving in a group of cancer patients to the expected
proportion that would have survived in an age- and sex-
comparable group of people from the general population
[12], was used in this analysis because we used all-cause
mortality from a population-based cancer registry.
Survival time for each case was calculated from the
month of diagnosis to the month of death or censoring
(31 December 2008) using life-table methods [13].
Expected survival was calculated using the Pohar-Perme
method [14]. We constructed SES-specific life tables for
each year 1996–2000 and 2004–2008 by collapsing all-
cause mortality data and corresponding population data
by LGA into the SES quintiles used for classifying cancer
cases. The period method [15] was used as in the previ-
ous study [6]. For each of these two ‘at risk’ periods
(1996–2000 and 2004–2008), we calculated 5-year rela-
tive survival by SES quintile for 10 individual cancers.
We chose the two ‘at risk’ periods for analysis to allow a
reasonable “lead in time” from the start of the diagnostic
cohort (1991) and to enable sufficient time for changes
in survival disparity to occur.
We investigated the effect of SES on survival for each
cancer using multivariate modelling to adjust for poten-
tially confounding variables. Firstly, we calculated the
relative excess risk (RER) of death due to cancer using a
Poisson-regression model [16]. In this model, the main-
effect variables were SES quintile, age group at diagnosis
(<49 years, 50–59 years, 60–69 years, 70–79 years,
80–89 years), sex, year of follow-up (1–5 years) and
cancer stage at diagnosis. We included the natural
logarithm of the population size as the offset variable.
The RER derived from this model is the ratio of the
Table 1 Five-year relative survival (%) by socioeconomic disadvantage for 10 cancers in NSW, Australia, 1996–2000 and 2004–2008
Cancer Five-year relative survival (%)
1996–2000 2004–2008
Least Second Third Fourth Most Least Second Third Fourth Most
Stomach (C16) 33.4 24.6 27.6 24.9 25.2 35.2 31.6 28.1 31.0 26.1
Colorectum (C18-21) 63.5 60.8 60.9 59.6 60.2 68.7 66.0 66.1 64.6 64.7
Liver (C22) 22.7 16.3 10.6 13.4 11.5 22.6 18.4 14.7 19.8 17.1
Lung (C33-34) 16.2 16.4 14.5 15.0 14.5 18.1 17.2 16.3 17.0 14.2
Melanoma (C43) 91.0 91.1 92.2 88.8 90.2 92.1 90.9 90.3 89.2 90.4
Breast (C50) 87.8 85.7 83.9 83.9 83.2 92.6 88.5 87.9 88.4 89.2
Cervix (C53) 71.7 72.9 74.3 69.0 73.2 76.2 72.0 75.5 73.4 60.9
Uterus (C54-55) 81.4 80.5 79.0 80.0 79.2 84.8 77.2 74.5 79.1 83.1
Ovary (C56-57) 44.4 41.6 38.5 38.9 38.2 44.5 44.5 44.7 39.4 41.0
Prostate (C61) 85.9 84.0 84.5 83.4 81.8 94.4 93.6 91.0 94.5 90.6
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excess risk of death in a given SES quintile to the ref-
erence SES group (the least disadvantaged quintile)
after controlling for the other factors included in the
model. Ninety-five percent confidence intervals (CIs)
for the RERs were calculated using the estimated co-
efficients and standard errors from the Poisson model.
Secondly, we added an interaction term between SES
quintile and time period to the model, to allow the
effect of SES to change between periods and then
used a likelihood ratio test between the nested models
to determine if this interaction was significant.
Finally, an estimate of the number of lives potentially
extendable to 5 years from cancer diagnosis was calcu-
lated for the four more disadvantaged SES quintiles for
each period. This was done in three steps. First, for each
of the four disadvantaged quintiles, we calculated the
difference between the number of stage-adjusted deaths
within a specific cancer cohort and that of an age-sex
equivalent group in the general population of the same
quintile [17]. These are the observed number of excess
deaths. Second, we calculated the number of deaths that
would have occurred if the stage-adjusted RER of cancer
death for these quintiles equalled that of the least disad-
vantaged quintile at 5 years from diagnosis [6]. These
are the optimum number of excess deaths. The number
of potentially extendable lives is equal to the difference
between the observed number of excess deaths and the
optimum number of excess deaths. This measure, similar
to that used in the EUROCARE-4 study [18], among
others [19, 20], has been used in different health settings
and is exchangeable with “avoidable deaths” and the
“number potentially saved” within a set time period
since diagnosis. A Pearson chi-square test was then used
to determine if the two proportions of “extendable” lives
were significantly different over time.
All significance tests with p-value <0.05 were taken to
indicate statistical significance. Statistical analyses were
completed using STATA software, v13.1 (StataCorp LP:
College Station, TX).
Results
A total of 380,306 cases diagnosed between 1991 and
2008 that were prevalent cases between periods of
1996–2000 and 2004–2008 were identified. About 0.7 %
(2 663 cases) were excluded from analysis due to being
notified to the registry by death certificate only or first
identified at post-mortem, while a further 150 cases were
excluded due to missing SES data. In total, 139,234
cases at-risk in 1996–2000 and 238,259 cases at-risk
in 2004–2008 were included in the final cohort (online
Additional file 1: Table S1). The numbers of cases
included in the analysis increased over time and were rela-
tively evenly distributed across the socioeconomic quin-
tiles in both periods. Liver, breast, ovarian and prostate
cancers saw higher case numbers in the less
disadvantaged SES groups, whereas the opposite trend
occurred for lung cancer.
Relative survival increased over time for the majority
of cancers, as shown in Table 1. However, the socio-
economic disparities observed in the first period
(1996–2000) remain broadly similar in the late period
(2004–2008).
Figure 1 shows the results of the multivariable model-
ling: RERs by SES quintile (with the reference group
being the least disadvantaged quintile). Values of these
RER estimates and p-value of significance tests are pre-
sented in Table 2. During 1996-2000, the RER of death
was significantly higher for more disadvantaged patients
with stomach, colorectal, liver, lung, breast and prostate
cancers. No significant variation in RER was found for
melanoma, ovarian, cervix or uterine cancers. By the
period of 2004–2008, significant RER’s continued to
exist for, stomach, colorectal, liver, lung, breast, prostate
cancers, while RER variations in cervical and uterine
cancers became highly significant (p = 0.008 and 0.001
respectively). Melanoma and ovarian cancer again
showed no significant variation in RER of death by SES
in 2004–2008.
The total of excess deaths due to cancer in 1996–2000
was 25,420 for all 10 cancers, of which 2690 lives
(10.6 % of excess deaths) were potentially extendable if
the SES survival disparity did not exist (Table 3). The
corresponding number for 2004–2008 increased to
26,583, of which 4253 lives (16.0 % of excess deaths)
were potentially extendable. The increase in the pro-
portion of extendable lives over time was significant
(p < 0.001) for the majority of cancers. Lung, colorec-
tal and breast cancers respectively accounted for the
greatest numbers of extendable lives in both periods.
Discussion
We found that while survival for 10 cancers has either
remained stable or increased over time, patients living in
more disadvantaged areas of NSW have continued to
experience lower survival rates than the least disadvan-
taged patients for cancers of the stomach, colorectum,
liver, lung, female breast and prostate and new dispar-
ities have emerged for cervical and uterine cancer.
There are several strengths in the design and methods
of this study. Our population-based data reflect the
survival experience of people diagnosed with major types
of cancer in NSW Australia. We used a well-established
ecological study design and statistical methods, as used
previously and recommended for measuring socioeco-
nomic inequalities in health [6, 11]. In addition, we
provide two measures of socioeconomic disparity, one
relative (RER) and one absolute (number of lives poten-
tially extendable). The availability and adjustment for stage
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of disease at diagnosis data further strengthens our
analysis, as stage is widely known to be an important
predictor for cancer survival [21, 22].
A limitation of our study comes from the use of ag-
gregated area-level data to classify patients according
to SES. Individual level socioeconomic data for cancer
patients was not available for this study. However,
recent studies using individual-level socioeconomic
data detected comparable trends in cancer survival
disparities [20, 23], suggesting a similar impact of
individual and area-based measures of SES on cancer
survival. Area-level methods for measuring health
disparities have been validated previously and were
shown to appropriately detect trends in survival in-
equalities [24]. In addition, the index used in this study
has been extensively reviewed and validated using nine
different methods [11] and has been widely used as a
socioeconomic measure in numerous studies of different
health outcomes in Australia [6, 25, 26].
Previous research has shown that the definition of the
socioeconomic index generally has little impact on the
survival disparities detected [27]. Under Australia’s univer-
sal healthcare system, access to health care is (theoretic-
ally) independent of a patient’s financial resources. As
such, compared to the index used here, other income-
based or economic-disadvantage indicators of SES may be
less relevant to identifying disparities in this context.
Our results of increased survival from cancer overall
and continuing socioeconomic disparities in survival are
consistent with both current Australian and inter-
national evidence. Persistent survival disparities by SES
have been found for stomach [28], colorectal [29], liver
[30], lung [1], breast [1, 21, 31], cervical [1, 29], uterine
[29] and prostate [29, 31] cancers. The reasons for the
socioeconomic survival disparities are not thoroughly
understood, and evidence on contributing factors is both
limited and often inconclusive. Some factors thought
to contribute to survival disparities by SES relate to
Fig. 1 Relative excess risk* by socioeconomic disadvantage for 10 cancers in New South Wales, Australia, 1996–2000 and 2004–2008. *The RER of
the reference group (least disadvantaged SES quintile) was set to 1.00
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Table 2 Relative excess risk of death by socioeconomic disadvantage for 10 cancers in NSW, Australia, 1996–2000 and 2004–2008
Cancer type Relative excess risk of deatha and (95 % confidence interval)
1996–2000 2004–2008 p-valuec
Least 2nd 3rd 4th Most p-valueb Least 2nd 3rd 4th Most p-valueb
Stomach 1.00 1.19 (1.03, 1.37) 1.16 (1.00, 1.34) 1.20 (1.04, 1.39) 1.24 (1.07, 1.43) 0.04 1.00 1.05 (0.91, 1.22) 1.26 (1.08, 1.46) 1.19 (1.02, 1.39) 1.31 (1.13, 1.51) 0.001 0.40
Colorectum 1.00 1.05 (0.96, 1.14) 1.06 (0.97, 1.15) 1.12 (1.03, 1.23) 1.15 (1.05, 1.25) 0.01 1.00 1.06 (0.98, 1.16) 1.11 (1.02, 1.22) 1.12 (1.03, 1.23) 1.17 (1.07, 1.27) 0.005 0.93
Liver 1.00 1.08 (0.86, 1.34) 1.09 (0.86, 1.39) 1.35 (1.08, 1.69) 1.42 (1.13, 1.77) 0.008 1.00 1.11 (0.93, 1.32) 1.39 (1.16, 1.66) 1.35 (1.13, 1.60) 1.34 (1.13, 1.60) 0.0003 0.44
Lung 1.00 1.12 (1.05, 1.19) 1.12 (1.05, 1.20) 1.12 (1.05, 1.20) 1.17 (1.10, 1.25) <0.0001 1.00 1.12 (1.05, 1.19) 1.18 (1.11, 1.26) 1.19 (1.12, 1.27) 1.26 (1.19, 1.34) <0.0001 0.55
Melanoma 1.00 1.08 (0.85, 1.36) 0.93 (0.72, 1.21) 1.16 (0.90, 1.49) 1.05 (0.82, 1.34) 0.53 1.00 0.89 (0.72, 1.09) 0.96 (0.78, 1.18) 1.00 (0.81, 1.24) 0.93 (0.76, 1.15) 0.77 0.74
Breast 1.00 1.16 (1.01, 1.34) 1.26 (1.09, 1.45) 1.23 (1.06, 1.43) 1.25 (1.08, 1.44) 0.009 1.00 1.30 (1.11, 1.51) 1.38 (1.18, 1.62) 1.29 (1.10, 1.52) 1.24 (1.05, 1.46) 0.001 0.74
Cervix 1.00 0.99 (0.72, 1.37) 1.24 (0.89, 1.72) 1.22 (0.88, 1.69) 1.04 (0.75, 1.44) 0.52 1.00 1.07 (0.72, 1.58) 1.09 (0.72, 1.63) 1.23 (0.82, 1.83) 1.71 (1.20, 2.43) 0.008 0.11
Uterus 1.00 1.13 (0.78, 1.63) 1.30 (0.90, 1.90) 1.25 (0.85, 1.86) 1.39 (0.97, 1.99) 0.43 1.00 1.35 (0.97, 1.90) 2.12 (1.53, 2.95) 1.61 (1.14, 2.27) 1.32 (0.92, 1.88) 0.0001 0.21
Ovary 1.00 1.07 (0.88, 1.29) 1.15 (0.94, 1.41) 1.15 (0.93, 1.42) 1.18 (0.96, 1.44) 0.48 1.00 1.00 (0.83, 1.20) 1.14 (0.93, 1.38) 1.21 (0.99, 1.47) 1.07 (0.89, 1.30) 0.25 0.87
Prostate 1.00 1.12 (0.94, 1.33) 1.14 (0.95, 1.36) 1.14 (0.94, 1.37) 1.32 (1.11, 1.56) 0.03 1.00 1.33 (1.07, 1.66) 1.51 (1.21, 1.89) 1.29 (1.02, 1.62) 1.34 (1.08, 1.66) 0.008 0.35
aAdjusted for age group, sex, year of follow-up and stage at diagnosis in a Poisson model
bWald test for the effect of SES quintiles in the Poisson model
cWald test for interaction between time period and SES quintiles
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differences in diagnosis and treatment factors, patient
characteristics and health care system features [2].
Previous studies of ovarian cancer survival have also
found no association with SES [6, 32]. The non-
specific nature of symptoms and lack of a definitive
screening-diagnostic test could explain this finding, as
the majority of diagnoses in all socioeconomic groups
in NSW in both periods occurred at an unknown or
already advanced stage (Additional file 2: Table S2),
by which point effective treatment options are limited
[33]. Despite Australia having the highest incidence of
melanoma worldwide [5] we found no significant vari-
ation in survival by SES in NSW, which is consistent
with previous findings [34]. This finding is likely asso-
ciated with the time–delayed effects of long running
and effective skin cancer awareness campaigns in
Australia, which have developed a strong culture of
protective behaviours [35, 36]. Patient ethnicity has been
associated with both melanoma incidence and survival
internationally [37, 38] though this data is not recorded by
the registry and so any potential confounding of survival
rates by ethnicity could not be controlled for in our ana-
lysis. Australian evidence of this association is both limited
and inconclusive [39]. Data on anatomic location of
melanomas was not included in this study, but previ-
ous Australian studies reported that melanomas most
commonly occurred on the trunk and limbs, areas
which have relatively higher survival rates [40], and
that anatomic location of melanomas did not vary
significantly by SES [34, 41].
We found significant differences in the distribution
of stage at diagnosis between SES groups, with low
SES patients more often presenting at more advanced
or unknown stage for several cancers (online
Additional file 2: Table S2) as reported previously
[42]. This is consistent with evidence of lower screen-
ing participation among more disadvantaged groups
in Australia [43] and internationally [44]. However
this stage differential by SES is unlikely to explain the
survival differential observed in this study, because
adjusting for spread of cancer did not greatly alter our es-
timates. While some misclassification of recorded stage
information by the Registry has been reported [45, 46],
our findings suggest that increasing early diagnosis of
cancers is less important than improving non-
diagnostic factors, such as patient lifestyle and treat-
ment factors, in reducing survival disparities in NSW.
Notable exceptions to this were cervical and prostate
cancers, which both had significant survival differen-
tials over time prior to stage adjustment that became
insignificant after adjustment. Consequently, socioeco-
nomic variation in rates of early diagnosis may be a
possible contributor to disparities in cervical and prostate
cancer survival.
Patient lifestyle factors may impact on cancer survival
by affecting overall health. Australian and international
reports have shown that lower socioeconomic groups
had significantly higher occurrences of poor lifestyle be-
haviours [47, 48]. Some lifestyle factors such as smoking
[48] and comorbidities [49] have been shown to directly
Table 3 Number of lives that might be extended beyond 5 years from diagnosis for 10 cancers in NSW, Australia 1996–2000 and
2004–2008
Cancer Number of lives potentially extended p-valuec
1996–2000 2004–2008
Number of
excess deaths
Lives potentially
extendedb
Proportion of
excess deaths (%)
Number of
excess deaths
Lives potentially
extendedb
Proportion of
excess deaths (%)
Stomach 1967 316 16.1 1895 324 17.1 0.389
Colorectum 6069 443 7.3 6189 606 9.8 <0.001
Liver 739 137 18.6 1312 312 23.8 0.006
Lung 9729 1090 11.2 11,002 1779 16.2 <0.001
Melanoma 941 0a 0 1213 0a 0
Breast 2188 393 17.9 1855 472 25.5 <0.001
Cervix 388 0a 0 318 92 28.9 <0.001
Uterus 356 0a 0 474 256 54.0 <0.001
Ovary 970 0a 0 1051 0a 0
Prostate 2073 311 15.0 1275 411 32.3 <0.001
All of the above 25,420 2690 10.6 26,583 4253 16.0 <0.001
aRER coefficients are not significant in the relative survival model for specific cancer
bEstimated by equating the RER of death due to cancer in the four more disadvantaged SES quintiles to that of the least disadvantaged quintile and calculating
the difference in number of cancer deaths
cPearson chi-square test of the difference between proportions of excess deaths over time (two periods)
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impact on the benefits of cancer treatment. However, a
recent population-based study in the US found that
socioeconomic disparities in breast cancer survival con-
tinued after controlling for several comorbid conditions
[50], suggesting that variations in comorbidity cannot
fully explain survival disparities. While we did not
specifically adjust for patient comorbid conditions in our
study, we did use SES-specific life tables for relative
survival calculations to reduce the effect on mortality
from different levels of competing causes of death across
the population.
Variation in cancer management by SES may also
contribute to disparities in survival, as patients of lower
SES are more likely to receive sub-optimal or non-
guideline therapy [21, 28]. Reduced compliance with rec-
ommended treatment regimes in low SES patients may
also contribute to lower survival rates [51]. Australia’s
universal healthcare system should provide consistent
access to cancer treatments to all socioeconomic groups.
However, it has been suggested that poorer survival in
patients from lower socioeconomic areas in Australia is
affected more by health system features, such as unequal
access to specialist treatment centres across NSW [52].
We did not have access to information on treatment or
patient management in this study, so we were unable to
investigate these suggestions further.
The number of lives that might be extended beyond
5 years from diagnosis has been used previously to
highlight the importance of socioeconomic survival
disparities and demonstrate the potential public health
benefits of improving cancer services [6, 17, 20, 53].
Estimating the number of these “avoidable deaths” (or
lives “potentially saved”) can assist health authorities
in allocating cancer services and resources to areas of
greatest need, and increase attention on the need to
further explore causes of socioeconomic variation in
survival [17]. The increased number of reported
avoidable deaths over time reflects both the higher
incidence and improved cancer survival in NSW. The
observed increases in the percentage of total excess
deaths that are avoidable emphasises the trend of
persistent cancer survival disparities between socio-
economic groups in NSW. These results indicate that
the greatest benefit would be derived from reducing
survival disparities for lung cancer patients, and that
focused health and social policies should be imple-
mented to address these disparities, as suggested pre-
viously [6]. Additional benefit would also be achieved
by reducing disparities in colorectal cancer survival.
Conclusions
In conclusion, we have reported that survival disparities
by area-level SES have persisted over time for several
cancers in NSW after adjusting for stage at diagnosis.
While the causes of these socioeconomic disparities
in survival are not thoroughly understood, variations
in treatment, patient characteristics and health system
factors may contribute. Despite increased awareness
of SES disparities in cancer survival, and overall
increases in cancer survival, this study suggests that
recent health and social policies in NSW have not
been effective in reducing socioeconomic inequalities
in survival.
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